Opus Genetics (IRD) EBIT Growth (1y) (2011 - 2026)
Powered by 
Analysis
Opus Genetics (IRD) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 269.85% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1,528.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -36.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 99.51% |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | -85.04% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -85.04% |
| Mar 31, 2026 | -44.67% |
| Dec 31, 2025 | 69.88% |
| Sep 30, 2025 | -3.77% |
| Jun 30, 2025 | -6.94% |
| Mar 31, 2025 | -28.81% |
| Dec 31, 2024 | -600.48% |
| Sep 30, 2024 | -225.41% |
| Jun 30, 2024 | -54.54% |
| Mar 31, 2024 | -25.72% |
| Dec 31, 2023 | -115.87% |
| Sep 30, 2023 | 240.72% |
| Jun 30, 2023 | -9.13% |
| Mar 31, 2023 | 5.79% |
| Dec 31, 2022 | 656.26% |
| Sep 30, 2022 | -7.23% |
| Jun 30, 2022 | 30.81% |
| Mar 31, 2022 | -25.49% |
| Dec 31, 2021 | 56.14% |
| Sep 30, 2021 | -117.25% |